ArticleInternational journal of colorectal disease2025
Clostridioides difficile co-infection worsens prognosis in inflammatory bowel disease in patients with cytomegalovirus colitis.
Article in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytomegalovirus (CMV) colitis and Clostridioides difficile infection (CDI) are both linked to disease exacerbation and poor prognosis in patients with inflammatory bowel disease (IBD). Nonetheless, the effect of co-infection on clinical outcomes in individuals with IBD remains underexplored. This retrospective study was designed to assess the clinical outcomes and determine predictors of co-infection with CMV and CDI in individuals with IBD.
methodsThis analysis involved hospitalized patients with IBD and confirmed CMV colitis (based on intestinal CMV immunohistochemical staining) and Clostridioides difficile toxin A/B test results, collected at the Linkou branch of Chang Gung Memorial Hospital between January 2001 and September 2023. The individuals in the study cohort were divided into two categories: those with CMV infection alone and those with CMV/CDI co-infection. Clinical manifestations, outcomes, and independent predictors of co-infection were assessed between the two groups.
resultsOverall, 53 IBD inpatients were enrolled in this study, with 37 assigned to the CMV group and 16 to the CMV/CDI co-infection group. The co-infection group experienced significantly more diarrhea (54.1% vs. 93.8%, p = 0.005) and abdominal pain (54.1% vs. 87.5%, p = 0.020) compared to the CMV group. Hospitalization duration (1 vs. 2.5 admissions, p = 0.005) and CMV recurrence (0 vs. 1 recurrences, p < 0.001) were higher in the co-infection group. Additionally, co-infection prolonged the time to clinical (1 vs. 5 months, p < 0.001), steroid-free (4 vs. 10 months, p = 0.001), endoscopic (8.3 vs. 17.5 months, p = 0.011), and histological remission (11 vs. 18 months, p = 0.021) compared to CMV infection alone. The cumulative incidence of clinical, steroid-free, endoscopic, and histological remission showed a delayed course in the co-infection group. Multivariable analysis revealed that biologic therapy was an independent predictor for CMV/CDI co-infection (OR 13.33, 95% CI 1.52-117.15, p = 0.02).
conclusionCo-infection of CMV and CDI among individuals with IBD results in more frequent hospitalizations, higher CMV recurrence rates, and prolonged disease remission compared to CMV colitis alone. The administration of biologic therapy increases the risk of co-infection, emphasizing the importance of careful management in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.